Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland

Roche swallows US breast cancer drug firm

Share this article

Roche swallows US breast cancer drug firm
Photo: Roche
12:27 CEST+02:00
Swiss pharmaceutical group Roche said on Wednesday that it was buying Seragon Pharmaceuticals, a US biotechnology firm specializing in a new way to fight breast cancer, in a deal worth up to $1.7 billion.

Seragon, a privately held outfit located in California, is developing a new generation of treatments for the most common form of breast cancer, the Basel-based company said in a statement.
   
Roche said its Genentech subsidiary would be acquiring Seragon, putting $725 million in cash upfront and adding up to another $1 billion if "certain predetermined milestones" are met.

The deal is expected to be sealed by the end of September if anti-trust regulators raise no objection.

Get notified about breaking news on The Local

Share this article

The Local is not responsible for content posted by users.
Become a Member or sign-in to leave a comment.

From our sponsors

‘No other place in Europe has such as high density of talent'

London has always had a certain allure that pulls in entrepreneurs from near and far. As one of the world's most connected cities, a top financial centre and a multicultural melting pot, countless professionals from Europe and beyond are drawn to London like moths to a flame.